GROUP

Our group aims to develop new therapeutic interventions to improve the diagnosis and prognosis of patients suffering from cancer related to the digestive system, mainly based on the identification of molecular biomarkers such as ctDNA, miRNAs and DNA modifications.

We also conduct clinical trials in order to:
– validate new drugs or reuse others,
– demonstrate the predictive value of biomarkers and,
– determine the recommended dose for the treatment.

At the level of laboratory research, we studied mechanisms of resistance to treatments and also sought new biomarkers in liquid biopsies (cDNA, microRNAs) for early diagnosis, monitoring and prediction of therapeutic effects in patients with gastrointestinal neoplasms.